Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melatonin in Relapsing Multiple Sclerosis
NCT03498131Phase 1Completed
- Start
- May 2018
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of melatonin in multiple sclerosis (MS) (2 arms). Primary endpoint: 24 hour urinary 6-sulfatoxymelatonin (6SMT) at Month 12. Started May 2018; status: completed.
02
Drugs
melatonin
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT03498131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03498131.